The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial
Objective The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and...
Gespeichert in:
| Veröffentlicht in: | Human psychopharmacology 2016-03, Vol.31 (2), p.103-112 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 112 |
|---|---|
| container_issue | 2 |
| container_start_page | 103 |
| container_title | Human psychopharmacology |
| container_volume | 31 |
| creator | Iranpour, Negar Zandifar, Atefeh Farokhnia, Mehdi Goguol, Amirhossein Yekehtaz, Habibeh Khodaie-Ardakani, Mohammad-Reza Salehi, Bahman Esalatmanesh, Sophia Zeionoddini, Atefeh Mohammadinejad, Payam Zeinoddini, Arefeh Akhondzadeh, Shahin |
| description | Objective
The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia.
Methods
In this randomized, double‐blind, placebo‐controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study.
Results
At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores (p |
| doi_str_mv | 10.1002/hup.2517 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1776647333</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3972189501</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4907-3f47247297e98c65ed481dc7c52da92606ca3acc536765b95af7f77b5098f9a63</originalsourceid><addsrcrecordid>eNqNkV1rFDEUhgdR7LYK_gIJeOPN1MxHvryzi26FUr1o8TJkMmc6WbPJmGRat_-j_9csu1YQBA85HEie80B4i-JVhU8rjOt34zyd1qRiT4pFhYUoK8zY02KBOSclrev6qDiOcY1xfsPieXFUU04oFWRRPFyNgGAYQKeI_IAm42-sSereO0CqX8-3yiWURghq2iLvkIMblcwtoLjdTMlv9lv5Clw23Jk0Ij0G74xGUY_m3k9jAGfUe6RQ7-fOQtlZ43qkck9Waeh8qb1LwVsLPUrBKPuieDYoG-HlYZ4U158-Xi3Py4svq8_LDxelbgVmZTO0rM5HMBBcUwJ9y6teM03qXomaYqpVo7QmDWWUdIKogQ2MdQQLPghFm5Pi7d47Bf9jhpjkxkQN1ioHfo6yYozSljW5_gOt2pbXnGf0zV_o2s_B5Y_sKMwEx037R6iDjzHAIKdgNipsZYXlLlWZU5W7VDP6-iCcuw30j-DvGDNQ7oE7Y2H7T5E8v_56EB54ExP8fORV-C4paxiR3y5X8vJsdcZ4s5Rt8wuajrw8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1770798034</pqid></control><display><type>article</type><title>The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Iranpour, Negar ; Zandifar, Atefeh ; Farokhnia, Mehdi ; Goguol, Amirhossein ; Yekehtaz, Habibeh ; Khodaie-Ardakani, Mohammad-Reza ; Salehi, Bahman ; Esalatmanesh, Sophia ; Zeionoddini, Atefeh ; Mohammadinejad, Payam ; Zeinoddini, Arefeh ; Akhondzadeh, Shahin</creator><creatorcontrib>Iranpour, Negar ; Zandifar, Atefeh ; Farokhnia, Mehdi ; Goguol, Amirhossein ; Yekehtaz, Habibeh ; Khodaie-Ardakani, Mohammad-Reza ; Salehi, Bahman ; Esalatmanesh, Sophia ; Zeionoddini, Atefeh ; Mohammadinejad, Payam ; Zeinoddini, Arefeh ; Akhondzadeh, Shahin</creatorcontrib><description>Objective
The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia.
Methods
In this randomized, double‐blind, placebo‐controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study.
Results
At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores (p < 0.001) as well as PANSS total scores (p = 0.01) compared with the placebo group.
Conclusion
These findings suggest the probable efficacy of pioglitazone as an augmentation therapy in reducing the negative symptoms of schizophrenia. Copyright © 2016 John Wiley & Sons, Ltd.</description><identifier>ISSN: 0885-6222</identifier><identifier>EISSN: 1099-1077</identifier><identifier>DOI: 10.1002/hup.2517</identifier><identifier>PMID: 26856695</identifier><identifier>CODEN: HUPSEC</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Adult ; Antipsychotic Agents - adverse effects ; Antipsychotic Agents - therapeutic use ; Chronic Disease ; clinical trial ; Double-Blind Method ; Drug Therapy, Combination ; Female ; Humans ; Iran ; Male ; negative symptoms ; pioglitazone ; Psychiatric Status Rating Scales ; Risperidone - therapeutic use ; schizophrenia ; Schizophrenia - drug therapy ; Schizophrenic Psychology ; thiazolidinedione ; Thiazolidinediones - adverse effects ; Thiazolidinediones - therapeutic use ; Time Factors ; Treatment Outcome</subject><ispartof>Human psychopharmacology, 2016-03, Vol.31 (2), p.103-112</ispartof><rights>Copyright © 2016 John Wiley & Sons, Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4907-3f47247297e98c65ed481dc7c52da92606ca3acc536765b95af7f77b5098f9a63</citedby><cites>FETCH-LOGICAL-c4907-3f47247297e98c65ed481dc7c52da92606ca3acc536765b95af7f77b5098f9a63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fhup.2517$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fhup.2517$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27903,27904,45553,45554</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/26856695$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Iranpour, Negar</creatorcontrib><creatorcontrib>Zandifar, Atefeh</creatorcontrib><creatorcontrib>Farokhnia, Mehdi</creatorcontrib><creatorcontrib>Goguol, Amirhossein</creatorcontrib><creatorcontrib>Yekehtaz, Habibeh</creatorcontrib><creatorcontrib>Khodaie-Ardakani, Mohammad-Reza</creatorcontrib><creatorcontrib>Salehi, Bahman</creatorcontrib><creatorcontrib>Esalatmanesh, Sophia</creatorcontrib><creatorcontrib>Zeionoddini, Atefeh</creatorcontrib><creatorcontrib>Mohammadinejad, Payam</creatorcontrib><creatorcontrib>Zeinoddini, Arefeh</creatorcontrib><creatorcontrib>Akhondzadeh, Shahin</creatorcontrib><title>The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial</title><title>Human psychopharmacology</title><addtitle>Hum. Psychopharmacol Clin Exp</addtitle><description>Objective
The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia.
Methods
In this randomized, double‐blind, placebo‐controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study.
Results
At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores (p < 0.001) as well as PANSS total scores (p = 0.01) compared with the placebo group.
Conclusion
These findings suggest the probable efficacy of pioglitazone as an augmentation therapy in reducing the negative symptoms of schizophrenia. Copyright © 2016 John Wiley & Sons, Ltd.</description><subject>Adult</subject><subject>Antipsychotic Agents - adverse effects</subject><subject>Antipsychotic Agents - therapeutic use</subject><subject>Chronic Disease</subject><subject>clinical trial</subject><subject>Double-Blind Method</subject><subject>Drug Therapy, Combination</subject><subject>Female</subject><subject>Humans</subject><subject>Iran</subject><subject>Male</subject><subject>negative symptoms</subject><subject>pioglitazone</subject><subject>Psychiatric Status Rating Scales</subject><subject>Risperidone - therapeutic use</subject><subject>schizophrenia</subject><subject>Schizophrenia - drug therapy</subject><subject>Schizophrenic Psychology</subject><subject>thiazolidinedione</subject><subject>Thiazolidinediones - adverse effects</subject><subject>Thiazolidinediones - therapeutic use</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>0885-6222</issn><issn>1099-1077</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkV1rFDEUhgdR7LYK_gIJeOPN1MxHvryzi26FUr1o8TJkMmc6WbPJmGRat_-j_9csu1YQBA85HEie80B4i-JVhU8rjOt34zyd1qRiT4pFhYUoK8zY02KBOSclrev6qDiOcY1xfsPieXFUU04oFWRRPFyNgGAYQKeI_IAm42-sSereO0CqX8-3yiWURghq2iLvkIMblcwtoLjdTMlv9lv5Clw23Jk0Ij0G74xGUY_m3k9jAGfUe6RQ7-fOQtlZ43qkck9Waeh8qb1LwVsLPUrBKPuieDYoG-HlYZ4U158-Xi3Py4svq8_LDxelbgVmZTO0rM5HMBBcUwJ9y6teM03qXomaYqpVo7QmDWWUdIKogQ2MdQQLPghFm5Pi7d47Bf9jhpjkxkQN1ioHfo6yYozSljW5_gOt2pbXnGf0zV_o2s_B5Y_sKMwEx037R6iDjzHAIKdgNipsZYXlLlWZU5W7VDP6-iCcuw30j-DvGDNQ7oE7Y2H7T5E8v_56EB54ExP8fORV-C4paxiR3y5X8vJsdcZ4s5Rt8wuajrw8</recordid><startdate>201603</startdate><enddate>201603</enddate><creator>Iranpour, Negar</creator><creator>Zandifar, Atefeh</creator><creator>Farokhnia, Mehdi</creator><creator>Goguol, Amirhossein</creator><creator>Yekehtaz, Habibeh</creator><creator>Khodaie-Ardakani, Mohammad-Reza</creator><creator>Salehi, Bahman</creator><creator>Esalatmanesh, Sophia</creator><creator>Zeionoddini, Atefeh</creator><creator>Mohammadinejad, Payam</creator><creator>Zeinoddini, Arefeh</creator><creator>Akhondzadeh, Shahin</creator><general>Blackwell Publishing Ltd</general><general>Wiley Subscription Services, Inc</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>K9.</scope><scope>7X8</scope></search><sort><creationdate>201603</creationdate><title>The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial</title><author>Iranpour, Negar ; Zandifar, Atefeh ; Farokhnia, Mehdi ; Goguol, Amirhossein ; Yekehtaz, Habibeh ; Khodaie-Ardakani, Mohammad-Reza ; Salehi, Bahman ; Esalatmanesh, Sophia ; Zeionoddini, Atefeh ; Mohammadinejad, Payam ; Zeinoddini, Arefeh ; Akhondzadeh, Shahin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4907-3f47247297e98c65ed481dc7c52da92606ca3acc536765b95af7f77b5098f9a63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Antipsychotic Agents - adverse effects</topic><topic>Antipsychotic Agents - therapeutic use</topic><topic>Chronic Disease</topic><topic>clinical trial</topic><topic>Double-Blind Method</topic><topic>Drug Therapy, Combination</topic><topic>Female</topic><topic>Humans</topic><topic>Iran</topic><topic>Male</topic><topic>negative symptoms</topic><topic>pioglitazone</topic><topic>Psychiatric Status Rating Scales</topic><topic>Risperidone - therapeutic use</topic><topic>schizophrenia</topic><topic>Schizophrenia - drug therapy</topic><topic>Schizophrenic Psychology</topic><topic>thiazolidinedione</topic><topic>Thiazolidinediones - adverse effects</topic><topic>Thiazolidinediones - therapeutic use</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Iranpour, Negar</creatorcontrib><creatorcontrib>Zandifar, Atefeh</creatorcontrib><creatorcontrib>Farokhnia, Mehdi</creatorcontrib><creatorcontrib>Goguol, Amirhossein</creatorcontrib><creatorcontrib>Yekehtaz, Habibeh</creatorcontrib><creatorcontrib>Khodaie-Ardakani, Mohammad-Reza</creatorcontrib><creatorcontrib>Salehi, Bahman</creatorcontrib><creatorcontrib>Esalatmanesh, Sophia</creatorcontrib><creatorcontrib>Zeionoddini, Atefeh</creatorcontrib><creatorcontrib>Mohammadinejad, Payam</creatorcontrib><creatorcontrib>Zeinoddini, Arefeh</creatorcontrib><creatorcontrib>Akhondzadeh, Shahin</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Human psychopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Iranpour, Negar</au><au>Zandifar, Atefeh</au><au>Farokhnia, Mehdi</au><au>Goguol, Amirhossein</au><au>Yekehtaz, Habibeh</au><au>Khodaie-Ardakani, Mohammad-Reza</au><au>Salehi, Bahman</au><au>Esalatmanesh, Sophia</au><au>Zeionoddini, Atefeh</au><au>Mohammadinejad, Payam</au><au>Zeinoddini, Arefeh</au><au>Akhondzadeh, Shahin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial</atitle><jtitle>Human psychopharmacology</jtitle><addtitle>Hum. Psychopharmacol Clin Exp</addtitle><date>2016-03</date><risdate>2016</risdate><volume>31</volume><issue>2</issue><spage>103</spage><epage>112</epage><pages>103-112</pages><issn>0885-6222</issn><eissn>1099-1077</eissn><coden>HUPSEC</coden><abstract>Objective
The evident central role of inflammation, oxidative stress, and metabolic derangement in pathophysiology of negative symptoms of schizophrenia has opened new insights into probable pharmacological options for these symptoms. Pioglitazone is an antidiabetic agent with anti‐inflammatory and antioxidant properties. In this study, we evaluated the efficacy of pioglitazone as an adjunct to risperidone for reduction of negative symptoms in schizophrenia.
Methods
In this randomized, double‐blind, placebo‐controlled trial, 40 patients with chronic schizophrenia and a minimum score of 20 on the negative subscale of Positive and Negative Syndrome Scale (PANSS) were randomly allocated to receive risperidone plus either pioglitazone (30 mg/day) or placebo for 8 weeks. Patients' symptoms and adverse events were rated at baseline and weeks 2, 4, 6, and 8. The difference between the two groups in decline of PANSS negative subscale scores was considered as the primary outcome of this study.
Results
At the study endpoint, patients in the pioglitazone group showed significantly more improvement in PANSS negative subscale scores (p < 0.001) as well as PANSS total scores (p = 0.01) compared with the placebo group.
Conclusion
These findings suggest the probable efficacy of pioglitazone as an augmentation therapy in reducing the negative symptoms of schizophrenia. Copyright © 2016 John Wiley & Sons, Ltd.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>26856695</pmid><doi>10.1002/hup.2517</doi><tpages>10</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0885-6222 |
| ispartof | Human psychopharmacology, 2016-03, Vol.31 (2), p.103-112 |
| issn | 0885-6222 1099-1077 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1776647333 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Antipsychotic Agents - adverse effects Antipsychotic Agents - therapeutic use Chronic Disease clinical trial Double-Blind Method Drug Therapy, Combination Female Humans Iran Male negative symptoms pioglitazone Psychiatric Status Rating Scales Risperidone - therapeutic use schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology thiazolidinedione Thiazolidinediones - adverse effects Thiazolidinediones - therapeutic use Time Factors Treatment Outcome |
| title | The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T02%3A33%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20effects%20of%20pioglitazone%20adjuvant%20therapy%20on%20negative%20symptoms%20of%20patients%20with%20chronic%20schizophrenia:%20a%20double-blind%20and%20placebo-controlled%20trial&rft.jtitle=Human%20psychopharmacology&rft.au=Iranpour,%20Negar&rft.date=2016-03&rft.volume=31&rft.issue=2&rft.spage=103&rft.epage=112&rft.pages=103-112&rft.issn=0885-6222&rft.eissn=1099-1077&rft.coden=HUPSEC&rft_id=info:doi/10.1002/hup.2517&rft_dat=%3Cproquest_cross%3E3972189501%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1770798034&rft_id=info:pmid/26856695&rfr_iscdi=true |